Clinical Implications of Semaglutide in Patients with Gastroparesis

Mechanism of Action and Effects on Gastric Emptying

GLP-1 receptor agonists like semaglutide delay gastric emptying through central and peripheral pathways that inhibit vagal activity on the gut 3
This effect leads to reduced phasic gastric contractions, delayed gastric emptying, reduced gastric acid secretion, and increased fasting and postprandial gastric volumes 3
The delay in gastric emptying occurs through activation of GLP-1 receptors in the hypothalamus and brainstem nuclei, which modulate appetite, satiety, and gut motility 4

According to the American College of Cardiology guidelines, shorter-acting GLP-1 receptor agonists are not recommended in patients with clinically meaningful gastroparesis 1, 2
While the effect on gastric emptying is usually transient with longer-acting GLP-1 receptor agonists like semaglutide, caution is still warranted in patients with gastroparesis 1, 2

Patients with gastroparesis who are prescribed semaglutide should be closely monitored for worsening of symptoms including nausea, vomiting, early satiety, and abdominal pain 5
For patients with severe or refractory gastroparesis, alternative diabetes or weight management therapies should be considered 5, 6
Care should also be taken in patients with prior gastric surgery when considering semaglutide therapy 1, 2

Gradual dose titration of semaglutide is recommended to minimize gastrointestinal adverse effects 7, 8
Semaglutide may impact the absorption of some oral medications that require rapid onset of action due to its effect on gastric emptying 8
Patients with gastroparesis should be evaluated for the dominant refractory symptom to guide management efforts, particularly when considering escalation of medical management 6